Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) has provided an update.
Mesoblast Limited has applied to the ASX for quotation of 1,260,589 new fully paid ordinary shares, to be issued under the code MSB on April 7, 2026. The securities arise from previously announced transactions and will increase the company’s quoted share capital, modestly diluting existing holders but potentially enhancing liquidity in the stock.
The move signals continued capital-related activity as Mesoblast advances its programs, suggesting an ongoing need for funding typical of late-stage biotech developers. For investors, the additional shares reflect incremental expansion of the equity base, with implications for trading dynamics and valuation as the company pursues its strategic objectives.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australian-listed biotechnology company focused on developing and commercializing cellular medicines. Its primary activities center on regenerative therapies that target inflammatory diseases, cardiovascular conditions, and other serious disorders, with its shares traded on the ASX under the ticker MSB.
Average Trading Volume: 4,173,671
Technical Sentiment Signal: Hold
Current Market Cap: A$2.75B
See more insights into MSB stock on TipRanks’ Stock Analysis page.